The real-world clinical effectiveness of durvalumab in advanced biliary tract cancer: a mimic comparative analysis through survival data reconstruction.

Front Immunol · 2025 · PMC12669214 · PMID 41341598

Europe PMC DOI

hedged sentence

0.3500

closest p · 7.0× alpha

0.3500

boldest claim

The sentences

a slight trendp=0.35not close (p > 0.1)

(2024) ( 25 ), the occurrence of irAEs was found to be associated with a slight trend of better outcome with a mOS not reached versus 12 months (95% CI, 9.3-14.7; p=0.35) and mPFS of 11 months (95% CI, 3.4-18.5) versus 8 months (95% CI, 7.1-8.9; p=0.401).

also in 4,078 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.